Effect of Sacubitril/Valsartan in Patients with Acute Exacerbation of Chronic Heart Failure

Effect of Sacubitril/Valsartan in Patients with Acute Exacerbation of Chronic Heart Failure - Sacubitril/Valsartan and Acute Heart Failure

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046583

Enrollment

100

Registered

2022-01-10

Start date

2021-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Exacerbation of Heart failure

Interventions

Change of therapy from ACE-I/ARB to ARNI (100mg/day), followed by 14 days of treatment Continue treatment with ACE-I/ARB for 14 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with acute exacerbation of heart failure who require intensive care. (All patients were already administrated ACE-I or ARB) 2) Patients from whom written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients heart failure due to ST elevation myocardial infarction 2) Patients with end-stage chronic kidney disease (eGFR<30 mL/min/1.73m2) were excluded from present study. 3) Patients who satisfied the matters that requires attention in appended paper.

Design outcomes

Primary

Measure	Time frame
Changes to the natriuretic peptide families (BNP, NT-proBNP and ANP)	—

Secondary

Measure	Time frame
1) serum renin, aldosterone and AngiotensinII 2) medications 3) age, gender, presence of de novo or recurrent HF, etiology of HF, past medical history (risk factors for atherosclerosis [diabetes mellitus, hypertension, and dyslipidemia], and chronic kidney disease), vital signs (systolic blood pressure [SBP] and heart rate), presence of orthopnea, arterial blood gas data, laboratory data (blood urea nitrogen, creatinine, total bilirubin, sodium, potassium, hemoglobin, BNP, C-reactive protein [CRP] 4)left ventricular ejection fraction (LVEF) on echocardiography 5)long-term prognosis (all cause death and HF event within 1 year)	—

Measure

Time frame

1) serum renin, aldosterone and AngiotensinII 2) medications 3) age, gender, presence of de novo or recurrent HF, etiology of HF, past medical history (risk factors for atherosclerosis [diabetes mellitus, hypertension, and dyslipidemia], and chronic kidney disease), vital signs (systolic blood pressure [SBP] and heart rate), presence of orthopnea, arterial blood gas data, laboratory data (blood urea nitrogen, creatinine, total bilirubin, sodium, potassium, hemoglobin, BNP, C-reactive protein [CRP] 4)left ventricular ejection fraction (LVEF) on echocardiography 5)long-term prognosis (all cause death and HF event within 1 year)

—

Countries

Japan

Contacts

Public ContactAkihiro Shirakabe

Nippon Medical School Chiba Hokusoh Hospital Division of Intensive Care Unit

s6042@nms.ac.jp0476991111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026